Recently the Food and Drug Administration filled the regulatory vacuum surrounding electronic cigarettes, today we look at the evidence for the e-cig and the reaction from the press

By Sally Satel and Brad Rodu

The FDA (the Food and Drug Administration) in America is drafting regulations that would ban sales to youths but allow flavorings and set a two-year time frame for approval of existing vapor products.

Growing in popularity among smokers—about one in five tried an e-cigarette between 2010 and 2011, the latest years for which the Centers for Disease Control has data—the current market is estimated at $2.2 billion in the U.S., up from under $1 billion two years ago.

As Dr. Sanghavi, a  pediatric cardiologist,  rightly notes “Despite years of research, tons of spending on everything from nicotine patches to nicotine gum, and admonitions from physicians, no one has figured out a great way to help smokers quit.”

Do E-Cigs Help People Quit Smoking

In the U.S this is true. In Sweden, by contrast, there has been marked success with snus, a tiny pouch of tobacco that sits between a person’s cheek and gum. For 50 years its use by Swedish men has been associated with world-record low rates of smoking and smoking-attributable deaths, including lung, oral and throat cancers as well as cardiovascular events.

First, quitting is not the only measure of success: merely switching to e-cigarettes spares smokers the carcinogenic tar, not a trivial health advantage. Moreover, only eight percent of the 88 vapers expressed an intention to quit. If they had no desire to quit, there is no reason to think that use of e-cigs would make it more likely. In fact, the authors reported that “intention” to quit did predict quitting while electronic cigarette use, per se, did not.

Another important facet of the debate, as Sanghavi says, is the worry that vaping will serve a gateway function to actual smoking. Many critics of e-cigs consider this prospect ample reason to curtail marketing and availability to adults.

 How realistic is the gateway phenomenon?

The National Youth Tobacco Survey reveals that e-cigarette use (as little as a single puff within the last month) among high school students almost doubled from 2011 to 2012, from 1.5 percent to 2.8 percent. However, the same survey showed that cigarette use declined from 14.6 percent to 11.8 percent at the same time.

The central question is whether the small group of teens who reported trying e-cigarettes move on to smoking conventional ones. At this time, there are no reliable signs of this.

To date, then, data suggest that increased exposure to e-cigarettes isn’t encouraging more teens to smoke. Yet the numbers of youthful vapers are still so small that it’s too early to make definitive claims about the relationship between teen vaping and smoking.

Epidemiologists must continue to collect data on patterns of vaping and smoking among teens and adults. But they will also be following the advantages. After all, people switch to e-cigs because they are less hazardous than conventional ones. They don’t combust tobacco leaves, so vapers are not exposed to carcinogenic tars and harmful gases that cigarettes produce.

What’s more, e-cigarettes have advantages over nicotine patches and gums: They provide a quicker fix because the pulmonary route is the fastest practical way to deliver nicotine to the brain, and they offer appealing visual, tactile and gestural similarities to traditional cigarettes.

This is why so many public health experts are enthusiastic about the harm reduction properties of e-cigarettes. Harm reduction is an approach to risky behavior (smoking, in this case) that prioritizes minimizing damage (by cutting out tobacco combustion) rather than eliminating the behavior (by tolerating, even encouraging, vaping).

"For the first time in a century, we have an appealing alternative way to give addicted current smokers a satisfying way to give up their combustive products," said David J. Abrams, Professor in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health.

The risk, if any, of long-term inhalation of propylene glycol, the common substrate used for the nicotine solution, is not known—the devices have simply not been around long enough. In limited exposure, however, the U.S. Food and Drug Administration generally regards propylene glycol as safe; it is used in toothpaste, asthma inhalers and many other foods and cosmetics. Still, epidemiologists should monitor its effect on health, if any, over the long term.

And while there are also traces of nitrosamines, which are known carcinogens, they are present at levels comparable to medicinal products, such as nicotine gum and patches, and at concentrations 500 to 1,400 timeslower than in regular cigarettes. Cadmium, lead and nickel may be there, too, but in amounts and forms considered nontoxic. Also, e-cigarettes do provide nicotine, which can be addictive, but the health effects of nicotine are generally benign.

There are no data on the long-term use of e-cigarettes. Some risks may well be uncovered, but the almost certain likelihood of advantage to smokers will be too.

The crux of the issue is not, as Sanghavi put it, whether e-cigs encourage non-smokers to start up versus whether they help people quit. It’s not “either-or.” We need to know whether smokers who switch to e-cigarettes have lower levels of disease than their counterparts who continued smoke and how the health of committed vapers compares to those who wean themselves off e-cigs entirely. We also want to know if e-cigarettes are introducing non-smoking teens to cigarettes.

It’s not clear what the FDA will do with such information when, at least a decade from now, it becomes available. One hopes the agency wisely weighs the yet undiscovered costs with the still-to-be confirmed long-term benefits.

Sally Satel, M.D., is the W.H. Brady Fellow at the American Enterprise Institute. Brad Rodu is a Professor of Medicine at University of Louisville.

 

We are so sure you will love SMOKO, you can try a SMOKO E-Cigarette Starter Kit for FREE* (simply pay the UK Postage and Packaging) – CLICK HERE to get your E-Cigarette Starter Kit FREE!

About SMOKO Premium E-Cigarettes

SMOKO Premium Electronic Cigarettes is the UK’s leading brand of e-cigarettes.  Since starting over 4 years ago, SMOKO has helped prevent over 85,000,000 cigarettes being smoked and have helped our customers save over £32,500,000 in extra disposable income.

SMOKO E-Cigarettes contain only the highest quality, pharmaceutical-grade ingredients that are all Made in the UK – whereas the majority of e-cigarette brands sold in grocery and convenience stores, petrol stations and on-line use Chinese-made ingredients.

SMOKO Electronic Cigarettes contain only 4 ingredients vs. the 4,000 chemicals and 50 known carcinogens found in traditional cigarettes.

SMOKO – Amazing flavour, realistic smoking sensation and quality you can trust.

 

To read the whole article go to http://www.newrepublic.com/article/117568/e-cigarette-data-why-everyone-asking-wrong-questions